Abstract:Background Anti-CTLA-4 antibodies have brought about limited clinical benefit because severe toxicity limits dosing levels and/or duration. We used CTLA-4 knockin mice to screen for antibodies with higher anti-tumor activity but lower autoimmunity. We have revealed that the key for better safety and preclinical efficacy is preservation of CTLA-4 for immune tolerance and intratumorial Treg depletion. Our work established that, independent of blocking activities, mAbs that preserve CTLA-4 recycling maintain the physiological immune tolerance checkpoint function while allowing more efficient and selective elimination of tumor-infiltrating regulatory T cells, resulting in highest efficacy and lowest toxicity and was thus developed for clinical testing of all antibodies tested. 1–6 The antibody with best safety and efficacy profile, ONC-392 was developed for clinical testing. The first-in human studies showed that ONC-392 is safe and well tolerated. Remarkably, no irAE has been reported among patients who has received repeated dosing of 3.0 mg/kg and 10.0 mg/kg of ONC-392. The molecular and cellular characterization of ONC-392 will be presented. Methods In vitro binding and disassociation assay were determined between pH 4.0–7.0. The intracellular traffic of both antibodies and CTLA-4 molecules were visualized by confocal microscopy. The binding to human and mouse FcgRI, IIA, IIB, and III (A), FcRn as well as mouse FcgRIV were evaluated by surface plasmon resonance (SPR). Depletion of regulatory T cells in tumor and lymphoid tissues were determined by flow cytometry. Results ONC-392 is a pH-sensitive antibody that preserves CTLA-4 recycling. By preserving cell surface CTLA-4, Onco-392 preserves immune tolerance. Preserving CTLA-4 on tumor-infiltrating Treg contribute to more effective immunotherapy. In addition to its unique feature of pH sensitive binding, OncoC4 also have several important features in Fc. ONC-392 shown comparable binding to human FcgRI and IIIA as wild-type IgG1s. As expected from the mutations introduced, ONC-392 show about 6 fold higher affinity for FcRn than wild-type IgG1. Interestingly, ONC-392 has shown 7–10-fold reduction to FcgRIIB, which is generally considered to be a negative signaling FcR. ONC-392 binding to mouse FcgRI-IV was lower that WT IgG1. Conclusions Unlike other clinical anti-CTLA-4 antibodies, ONC-392 preserves CTLA-4 recycling and thus Treg function in the peripheral tissues. The higher cell surface CTLA-4 allows more efficient Treg depletion in the tumor microenvironment. In addition, despite reduced binding to mouse activating Fc?RI, III/IV, ONC-392 was more effective in intratumor Treg depletion in the mice. Therefore, lacking negative signaling from Fc?RIIB may also contribute to its anti-tumor activity. Trial Registration NCT04140526 References Du X, et al . Uncoupling therapeutic from immunotherapy-related adverse effects for safer andeffective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Res 2018; 28 :433–447. Du X, et al . A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. Cell Res 2018; 28 :416–432. Liu Y, Zheng P. How does an anti-CTLA-4 antibody promote cancer immunity? Trends Immunol 2018; 39 :953–956. Zhang Y, et al . Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. Cell Res 2019; 29 :609–627. Liu Y, Zheng P. Preserving the CTLA-4 checkpoint for safer and more effective cancer immunotherapy. Trends Pharmacol Sci 2020; 41 (1):4–12. Zhang P, et al . Mechanism- and immune landscape-based ranking of therapeutic responsiveness of 22 major human cancers to next generation anti-CTLA-4 antibodies. Cancers 2020; 12 :284.

Exploring The Main Mechanisms Of Anti-Tumor And Immunotherapy-Related Adverse Events For Safer And Effective Anti-Ctla-4 Immunotherapy

Abstract 945: Advancing Cancer Immunotherapeutics: A Focus on Characterization of Anti-Ctla-4 Mabs for Better Anti-Tumor Immunity and Less Toxicity

Uncoupling Therapeutic from Immunotherapy-Related Adverse Effects for Safer and Effective Anti-Ctla-4 Antibodies in CTLA4 Humanized Mice

Hijacking Antibody-Induced CTLA-4 Lysosomal Degradation for Safer and More Effective Cancer Immunotherapy

Soluble CTLA-4 Mutants Ameliorate Immune-Related Adverse Events but Preserve Efficacy of CTLA-4– and PD-1–targeted Immunotherapy

231 Molecular insights on safety and anti-tumor activity of a non-irAE-inducing anti-CTLA-4 monoclonal antibody ONC-392

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

Unveiling the Key Regulators

813 CD24Fc Ameliorates Immune-Related Adverse Events While Preserving Anti-Tumor Therapeutic Effect

Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy

CTLA-4 in Regulatory T Cells for Cancer Immunotherapy

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Clinical Adverse Reactions and Treatment Strategies of Tumor Immune Checkpoint Blockades

Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis

Elucidating CTLA-4's role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.